Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: A systematic literature review

Phlebology

Volumn 28, Issue 3, 2013, Pages 123-131

  Willenberg, T ^a,b   Smith, P C ^c   Shepherd, A ^a   Davies, A H ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c British Vein Institute   (United Kingdom)

Author keywords

Sclerotherapy; Varicose veins; Visual disturbance

Indexed keywords

POLIDOCANOL; SCLEROSING AGENT; TETRADECYL SULFATE SODIUM;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLEROTHERAPY; SYSTEMATIC REVIEW; TELANGIECTASIA; VARICOSIS; VISUAL DISORDER;

EMBOLISM; FEMALE; HUMANS; MALE; MEDLINE; POLYETHYLENE GLYCOLS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; SODIUM TETRADECYL SULFATE; TELANGIECTASIS; VARICOSE VEINS; VISION DISORDERS;

EID: 84879476941     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2012.012051     Document Type: Review

References (61)

1. Fischer R, Linde N, Duff C, Jeanneret C, Chandler JG, Seeber P. Late recurrent saphenofemoral junction reflux after ligation and stripping of the greater saphenous vein. J Vasc Surg 2001;34:236-40
2. Merchant RF, Pichot O. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. J Vasc Surg 2005;42:502-9; discussion 509
3. Mundy L, Merlin TL, Fitridge RA, Hiller JE. Systematic review of endovenous laser treatment for varicose veins. Br J Surg 2005;92:1189-94
4. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA. Sclerosants in microfoam. A new approach in angiology. Int Angiol 2001;20:322-9
5. Schadeck M, Allaert F. [Ultrasonography during sclerotherapy]. Phlebologie 1991;44:111-29; discussion 130
6. Darvall KA, Bate GR, Adam DJ, Silverman SH, Bradbury AW. Duplex ultrasound outcomes following ultrasoundguided foam sclerotherapy of symptomatic primary great saphenous varicose veins. Eur J Vasc Endovasc Surg 2010;40:534-9
7. Coleridge Smith P. Sclerotherapy and foam sclerotherapy for varicose veins. Phlebology 2009;24:260-9
8. Sarvananthan T, Shepherd AC, Willenberg T, Davies AH. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg 2011;55:243-51
9. Caggiati A, Franceschini M. Stroke following endovenous laser treatment of varicose veins. J Vasc Surg 2010;51:218-20
10. Harzheim M, Becher H, Klockgether T. [Brain infarct from a paradoxical embolism following a varices operation]. Dtsch Med Wochenschr 2000;125:794-6
11. Frullini A, Felice F, Burchielli S, Di Stefano R. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebology 2011;26:203-8
12. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with sclerosant foam. J Cardiovasc Surg (Torino) 2006;47:9-18
13. Bhogal R, Moffat CE. Foam sclerotherapy for bilateral varicose veins: bilateral vs interval unilateral procedures: Published abstract from the Venous Forum 3-4 April 2008. Phlebology 2008;23:201
14. Cabrera J, Redondo P, Becerra A, et al. Ultrasoundguided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004;140:667-73
15. Cavezzi A, Frullini A, Ricci S, Tessari A. Treatment of varicose veins by foam Sclerotherapy: two clinical series. Phlebology 2002;17:13-8
16. Ceulen RP, Sommer A, Vernooy K. Microembolism during foam sclerotherapy of varicose veins. N Engl J Med 2008;358:1525-6
17. Darke SG, Baker SJ. Ultrasound-guided foam sclerotherapy for the treatment of varicose veins. Br J Surg 2006;93:969-74
18. Frullini A. New technique in producing sclerosing foam in a disposable syringe. Dermatol Surg 2000;26:705-6
19. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg 2002;28:11-5
20. Gillet JL, Guedes JM, Guex JJ, et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1025 patients. Phlebology 2009;24:131-8
21. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg 2004;30:367-72; discussion 372
22. Morrison N, Neuhardt DL, Rogers CR, et al. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008;47:830-6
23. Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007;33:116-21
24. Park SW, Yun IJ, Hwang JJ, et al. Fluoroscopy-guided endovenous foam sclerotherapy using a microcatheter in varicose tributaries followed by endovenous laser treatment of incompetent saphenous veins: technical feasibility and early results. Dermatol Surg 2009; 35:804-12
25. Raymond-Martimbeau P. Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology 2009;24:114-9
26. Smith PC. Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006;32:577-83
27. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001;27:58-60
28. Wright D, Gobin JP, Bradbury AW, et al. Varisolve R polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006;21:180-90
29. Hartmann K, Harms L, Simon M. Reversible neurological deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009;38:648-9
30. Bradbury AW, Bate G, Pang K, Darvall KA, Adam DJ. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010;52:939-45
31. Henriet JP. Expérience durant trois années de la mousse de polidocanol dans le traitement des varices réticulaires et des varicosités. Phléblogie 1999;52:277-82
32. Alos J, Carreno P, Lopez JA, Estadella B, Serra-Prat M, Marinel-Lo J. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006;31:101-7
33. Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C. Efficacy of polidocanol foam vs liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. Eur J Vasc Endovasc Surg 2008;36:366-70
34. Gillet JL, Donnet A, Lausecker M, Guedes JM, Guex JJ, Lehmann P. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology 2010;25:261-6
35. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology 2010;25:124-31
36. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008;35:238-45
37. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins-prospective, blinded, placebo-controlled study. Dermatol Surg 2004;30:723-8; discussion 728
38. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert FA. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg 2003;29:1170-5; discussion 1175
39. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg 2004;30:718-22; discussion 722
40. Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg 2005;31:631-5; discussion 635
41. Kakkos SK, Bountouroglou DG, Azzam M, Kalodiki E, Daskalopoulos M, Geroulakos G. Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results. J Endovasc Ther 2006;13:357-64
42. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:123-8; discussion 128
43. Kunzlberger B, Pieck C, Altmeyer P, Stucker M. Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Dermatol Surg 2006;32:1410-3
44. Wallois P. [Incidents and accidents in the sclerosing treatment of varicose veins and their prevention]. Phlebologie 1971;24:217-24
45. Alexakis C, Caruelle JP, Sezeur A, et al. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 2004;53:85-90
46. Golman M, Bergan J. Complications and Adverse Sequelae of Sclerotherapy. 3rd edn. St Louis MO, USA: Mosby, 2001:231
47. McAusland S. The modern treatment of varicose veins. Med Press Circular 1939;201:404-10
48. Orbach EJ. Sclerotherapy of varicose veins. Utilization of an intravenous air block. Am J Surg 1944;LXVI:362-6
49. Cabrera C, Garcia-Olmedo C. Nuevo método de esclerosis en las varices tronculares. Patol Vasc 1995;4:35-7
50. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience 2009;161:327-41
51. Orsini C, Brotto M. Immediate pathologic effects on the vein wall of foam sclerotherapy. Dermatol Surg 2007; 33:1250-4
52. Guex JJ. Complications and side-effects of foam sclerotherapy. Phlebology 2009;24:270-4
53. Dreier JP, Kleeberg J, Alam M, et al. Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis. Exp Biol Med (Maywood) 2007;232:204-13
54. Parsi K, Connor DE, Pilotelle A, Low J, Ma DD, Joseph JE. Low concentration detergent sclerosants induce platelet activation but inhibit aggregation due to suppression of GPIIb/IIIa activation in vitro. Thromb Res 2012;130(3):472-8
55. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005;112:1063-72
56. Wright DD, Gibson KD, Barclay J, Razumovsky A, Rush J, McCollum CN. High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins. J Vasc Surg 2009;51:104-7
57. Regan JD, Gibson KD, Rush JE, Shortell CK, Hirsch SA, Wright DD. Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt. J Vasc Surg 2011;53:131-7
58. Hansen K, Morrison N, Neuhardt D, Salles-Cunha S. Transthoracic echocardiogram and transcranial Doppler detection of emboli after foam sclerotherapy of leg veins. J Vasc Ultrasound 2007;31:213-6
59. Breu FX, Guggenbichler S, Wollmann JC. 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa 2008;37(Suppl. 71):1-29
60. 2foam. Phlebologie 2012;41:77-88
61. Parsi K. Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications. Phlebology 2011;26:140-7